Annual Medicines for Europe and International Generic and Biosimilar medicines Association Conference 2020


    Join us for the Medicines for Europe and IGBA Conference in Athens next June to shape the 2030 agenda for the off-patent industry

    The important challenges on the horizon:

    • Bridging the access gaps that still affect patients in several parts of the world
    • Addressing the digitalisation of healthcare systems
    • Strengthening global supply security
    • Creating a long-lasting competitive environment
    • Developing the global market

    Our Conference from 17 – 19 June 2020 in Athens will reflect on the improvement to patients’ lives that this industry has achieved so far and will be pivotal to rolling out the off-patent industry proposal for the next decade.

    Find more details and register on https://www.medicinesforeurope.com/events/annual20/

    Event Name: Annual Medicines for Europe and International Generic and Biosimilar medicines Association Conference
    Event Venue: Divani Apollon Hotel Athens
    Event Date: 17 – 19 June 2020
    Event website link: https://www.medicinesforeurope.com/events/annual20/
    Event Organizer Name: Medicines for Europe
    Communication number (with country & area code): +31-6-41190824
    Email ID: trudy@medicinesforeurope.com

    Social Media Link’s: #IGBAmedicinesforEU

     

    Organiser: Medicines for Europe


    Medicines for Europe began over 20 years ago as the European Generics Medicines Association (EGA) with the goal of representing the emerging generic industry, and later growing to include biosimilar medicines to its portfolio. As the pharmaceutical industry and the healthcare environment within which it operates have evolved, so has our Association.

    When the EGA was first launched back in 1993, generic alternatives to branded medicines made up a fraction of the market. As more of these medicines came off-patent, and the benefits and value of generics to both patients and healthcare providers became clearer, so the provision of generic medicines has increased dramatically.

    Our members provide the essential medicines that European patients, healthcare professionals and healthcare systems rely on to treat the most acute and chronic diseases ailments covering a wide range of diseases from cardiovascular, to diabetes and cancer. Better access to the most effective therapies means millions more patients are getting better and living longer, while healthcare inequalities are being reduced.